Next Article in Journal
Effects of Passovia ovata Mistletoe on Pro-Inflammatory Markers In Vitro and In Vivo
Next Article in Special Issue
Effects of Allium hookeri Extracts on Hair-Inductive and Anti-Oxidative Properties in Human Dermal Papilla Cells
Previous Article in Journal
A Scoping Review of Genus Viscum: Biological and Chemical Aspects of Alcoholic Extracts
Previous Article in Special Issue
New Insights into the Phytochemical Profile and Biological Properties of Lycium intricatum Bois. (Solanaceae)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Plants
Volume 12
Issue 9
10.3390/plants12091813
plants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Potential Plant-Based New Antiplasmodial Agent Used in Papua Island, Indonesia

by
Raden Bayu Indradi
1,2,*,
Muhaimin Muhaimin
1,2,
Melisa Intan Barliana
1,3 and
Alfi Khatib
4
1
Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
2
Center of Herbal Study, Universitas Padjadjaran, Sumedang 45363, Indonesia
3
Center of Excellence in Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang 45363, Indonesia
4
Department of Pharmaceutical Chemistry, Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan 25200, Malaysia
*
Author to whom correspondence should be addressed.
Plants 2023, 12(9), 1813; https://doi.org/10.3390/plants12091813
Submission received: 21 March 2023 / Revised: 24 April 2023 / Accepted: 26 April 2023 / Published: 28 April 2023
(This article belongs to the Special Issue Bioprospecting of Natural Products from Medicinal Plants)
Browse Figures
Versions Notes

Abstract

:
Resistance to antimalarial medicine remains a threat to the global effort for malaria eradication. The World Health Organization recently reported that artemisinin partial resistance, which was defined as delayed parasite clearance, was detected in Southeast Asia, particularly in the Greater Mekong subregion, and in Africa, particularly in Rwanda and Uganda. Therefore, the discovery of a potential new drug is important to overcome emerging drug resistance. Natural products have played an important role in drug development over the centuries, including the development of antimalarial drugs, with most of it influenced by traditional use. Recent research on traditional medicine used as an antimalarial treatment on Papua Island, Indonesia, reported that 72 plant species have been used as traditional medicine, with Alstonia scholaris, Carica papaya, Andrographis paniculata, and Physalis minima as the most frequently used medicinal plants. This review aimed to highlight the current research status of these plants for potential novel antiplasmodial development. In conclusion, A. paniculata has the highest potential to be developed as an antiplasmodial, and its extract and known bioactive isolate andrographolide posed strong activity both in vitro and in vivo. A. scholaris and C. papaya also have the potential to be further investigated as both have good potential for their antiplasmodial activities in vivo. However, P. minima is a less studied medicinal plant; nevertheless, it opens the opportunity to explore the potential of this plant.

Graphical Abstract

1. Introduction

Currently, malaria remains the most severe parasitic disease globally. In 2019, the World Health Organization (WHO) estimated there had been 227 million cases and 558,000 deaths from malaria worldwide. In 2020, the number rose to approximately 241 million cases and 667,000 deaths after the COVID-19 pandemic disrupted services [1]. The reported global incidence rate reduced between 2000 and 2019. However, from 2015 to 2019, the change in the incidence slowed dramatically, and mortality rate reduction was reported to be slower in 2015–2019 [2]. The South-East Asia (SEA) region ranks second behind the African Region in the estimated number of malaria cases, and Indonesia is one of nine malaria-endemic countries in the SEA. The malaria elimination goal in Indonesia must be achieved by 2030 [2,3]. In 2021, the Indonesian Ministry of Health released the Indonesian Health Profile. The Annual Parasite Incidence (API) at the national level was at 0.94 per 1000 people. However, the Papua and Papua Barat provinces still record significantly higher numbers than national values, with 63.12 and 10.15 per 1000 people, respectively, and 95–99% received artemisinin combination treatment (ACT) [4].
Resistance to antimalarial medicine remains a threat to the global effort in malaria eradication. On the way to eliminate malaria, resistance to several drugs such as quinine, chloroquine, and sulfadoxine-pyrimethamine have been reported, mostly in endemic regions, including Indonesia [5]. A study in 2011 showed that in 1973–2005 and 1974–2010, 52% of Plasmodium falciparum and 48% of P. vivax positive samples were resistant to chloroquine. Chloroquine, a weak base, is protonated once it enters the digestive vacuole (DV) of parasites with acidic pH. This protonated chloroquine binds to heme that is toxic to the parasite, which is a byproduct of hemoglobin digestion inside DV, and is normally converted into nontoxic hemozoin by the parasite. The primary driver of chloroquine resistance is a mutation in the P. falciparum chloroquine resistance transporter gene (pfCRT) and the P. vivax chloroquine resistance transporter gene (pvCRT), which enables the efflux of protonated drug molecules from DV; thus, it will not bind to its target, heme. Another factor that contributed to chloroquine resistance is a mutation in the P. falciparum multidrug resistance (pfMDR1) gene and its ortholog P. vivax multidrug resistance (pvMDR1) gene in P. vivax, which reduced the transport of multidrugs, including chloroquine, into DV and leads to drug resistance [6,7].
In vivo and in vitro studies of Plasmodium falciparum from 1985 to 2011 have shown that 22% and 63%, respectively, were resistant to sulfadioxine-pyrimethamine and at least 6% were resistant to quinine in vitro [8]. The resistance to quinine is linked to amplified pfMDR1, whereas sulfadioxine-pyrimethamine resistance is linked to the P. falciparum dihydrofolate reductase (pfDHFR) and P. falciparum dihydroprotease (pfDHPS) gene mutations, which are the sites of action for sulfadioxine and pyrimethamine, respectively [6,9]. The latest report from the WHO regarding artemisinin resistance showed partial artemisinin resistance, which was defined as delayed parasite clearance detected in SEA, particularly in the Greater Mekong subregion, and in Africa, particularly in Rwanda and Uganda [1]. Artemisinin and its derivates affect a multitude of organellar and cellular processes including hemoglobin endocytosis, glycolysis, protein synthesis and degradation, and cell cycle regulation. The cleavage of its endoperoxide bridge by Fe-phytoporphyrin IX (Fe2+-heme) from parasite-digested hemoglobin activates artemisinin. The Fe2+-heme-artemisinin radicals then alkylate heme, protein, and lipids to amplify cytotoxic-reactive oxygen species, ultimately leading to cell death. The resistance of artemisinin is linked to the mutation of the parasite’s k13 gene (kelch13). Lowered k13 levels lead to a reduction in hemoglobin endocytosis, therefore, the digestion is reduced and a low level of Fe2+-heme presence leads to lesser activation of artemisinin [6]. These antiplasmodial agent resistance occurrences suggest that the discovery of a potential new drug with another mechanism might play an important role in overcoming emerging drug resistance.
Natural products have played an important role in drug development over the centuries, including in the development of antimalarial drugs. Quinine, a quinoline alkaloid from Cinchona sp., and artemisinin, a sesquiterpene lactone from Artemisia sp., are the best examples of antimalarial drugs developed from natural products. A study reported that >60% of antiparasitic new chemical entities identified from 1981 to 2014 were related to natural products [10]. Indonesia, having the second highest number of indigenous medicinal plants after the Amazon rainforest, has huge potential as a source of new antiparasitic drugs; however, Indonesia has not yet taken full advantage of this potential [11,12]. Indonesia is particularly unique in terms of medicinal plant utilization because the archipelago consists of 17,000 islands and approximately 6000 are inhabited, which leads to indigenous knowledge of traditional medicine and medicinal plants between the islands and ethnicities, including Papua Island where malaria is still high [4,13].
Recent research on traditional medicine used as antimalarial treatments on Papua Island, Indonesia, showed that 72 plant species have been used as traditional medicine. Among them, Pulai (Alstonia scholaris (L.) R. Br.), Papaya (Carica papaya L.), Sambiloto (Andrographis paniculata (Burm. f.) Nees), and Ciplukan (Physalis minima L.) were the most frequently mentioned by the locals to treat malaria [14]. Thus, this review highlights the current research status of these plants for potential novel antiplasmodial development.

2. Methods

Literature searches were performed in PubMed and ScienceDirect. The following search keywords were used in PubMed for each plant: (antimalarial[Title/Abstract] OR antiplasmodial[Title/Abstract]) AND (alstonia scholaris[Title/Abstract]); (antimalarial[Title/Abstract] OR antiplasmodial[Title/Abstract]) AND (carica papaya[Title/Abstract]); (antimalarial[Title/Abstract] OR antiplasmodial[Title/Abstract]) AND (andrographis paniculata[Title/Abstract]); and (antimalarial[Title/Abstract] OR antiplasmodial[Title/Abstract]) AND (physalis minima[Title/Abstract] OR physalins[Title/Abstract]). Keywords used in ScienceDirect included Alstonia scholaris AND (antimalarial OR antiplasmodial), Carica papaya AND (antimalarial OR antiplasmodial), andrographis paniculata AND (antimalarial OR antiplasmodial), and Physalis minima AND (antimalarial OR antiplasmodial), all in title, abstract, and keywords. The flow diagram is shown in Figure 1.

3. Alstonia scholaris (L.) R. Br.

A. scholaris of the Apocynaceae family is a large, buttressed, evergreen tree that is 6–10 m in height (Figure 2). It is widespread in the tropical parts of Asia and Africa [15,16]. It is commonly known as the Devil’s tree, milkwood pine, and white cheese wood [15]. In Indonesia, it is known as pulai and locally in Papua Island, it is known as arasue, pohon susu, kayu susu, igeii, aikahahe, ibuong, and yepaa [14].

3.1. Ethnopharmacology

In various traditional medicines, A. scholaris has been used as and is considered an important medicinal plant. It is commonly used to treat fever, diarrhea, malaria, dysentery, dyspepsia, asthma, bronchitis, as an antidiabetic, etc. [20,21]. In the Indian traditional medicine system, Ayurveda, the bark is used as a tonic, alterative, febrifuge, and gastrointestinal sedative. It is also useful in the treatment of malarial fever [22]. In traditional Chinese medicine, the leaf is used to treat chronic respiratory diseases [23]. In Indonesia, mainly on Papua Island, the bark is used to treat fever and malaria. According to the Papua Health Department, local people use dried bark. It was soaked overnight and one glass is consumed daily to combat malaria, until the disease is cured. Alternatively, fresh bark is chewed directly, and then the liquid or juice is swallowed. However, how much bark should be used as medication has not been mentioned [14,24].

3.2. Phytochemistry

A. scholaris is rich in alkaloids, mainly indole alkaloids. The bark contains several substances, such as ditamine, echitamine, echitenine, echicaoutchin, echicerin, echitin, echitein, echiretin, ditain, ditamine, losbanine, 6,7-secoangustilobine B, Nb-demethyl echitmaine, 17-O-acetyl echitamine, picraline deacetyl, lupeol, β-sitosterol, alstonidine, alstonine, villalstonine, and macrocarpamine [22,25]. The leaf contains alkaloid compounds, such as scholaricine, 19-epischolaricine, vallesamine, picrinine, (19,20) E-alstoscholarine, (19,20) Z-alstoscholarine, 5-methoxyaspidophylline, picralinal, 5-methoxystrictamine, scholarisine A, scholarisines H-O, (±)-scholarisine II, alstorisine A, scholarisines B-G, normavacurine-21-one, 5-hydroxy-19, 20-E-alschomine, 5-hydroxy-19, 20-Z-alschomine, altoscholarisines A-J, alstoniascholarines A-K, alstoniascholarines L-Q, alstolactines A-C, and alstonitrine A [16,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. The leaf also contains non-alkaloids, namely, scholareins A-D, megastigmane-3β, 4α, 9-triol, and 7-megastigmene-3,6,9-triol [41,42]. A. scholaris compounds are well-investigated thus it could be advantageous to explore known compounds for their pharmacological activities.

3.3. Antiplasmodial Activity

Several in vitro and in vivo studies have investigated the antiplasmodial activities of A. scholaris. Two in vitro studies on the chloroquine-sensitive P. falciparum strain 3D7 were performed by Taek et al. (2021) and Abdillah et al. (2015) who investigated the activity of stem bark extract. The only difference in their method was the solvent used in the extraction by maceration, which were 95% and 70% ethanol. However, a quite significant difference was found in the IC50 result, where extraction with 70% ethanol gives a strong antiplasmodial activity (0.165 µg/mL) compared to 95% ethanol with only moderate activity (15.46 µg/mL) [43,44]. In 2006, Ouattara et al. categorized an extract as very active or strong antiplasmodial if the IC50 is <5 μg/mL, active or moderate antiplasmodial if IC50: 5–50 μg/mL, less active or weak antiplasmodial if IC50: 50–100 μg/mL, and inactive if IC50: >100 μg/mL [45]. However, what caused the difference is still unclear. Only Abdillah et al. conducted phytochemical screening; thus, no comparison can be performed. However, the difference in the activity of 70% and 96% ethanol extract showed that more polar compounds that should have been extracted better by 70% ethanol might have demonstrated better in vitro antiplasmodial activity. The environment where the plant grows also plays an important role, as it could result in different chemical compositions in plants. Keawpradub et al. (1999) compared the in vitro antiplasmodial activity against the P. falciparum multidrug-resistant K1 strain from a methanolic extract using leaves, stem bark, and root bark of three Alstonia species from Thailand. The result showed that the stem bark of A. scholaris was second best with the lowest IC50 of 181.4 µg/mL, which is considered inactive, much weaker than the root bark of Alstonia macrophylla with the lowest IC50 of 5.7 µg/mL [45,46]. This result suggested that the methanolic extract of A. scholaris might not well deal with the P. falciparum multidrug-resistant strain, although other studies on the chloroquine-sensitive strain gave a strong and moderate activity [43,44]. This study also tested villalstonine and macrocarpamine which were isolated from A. macrophylla and well known to be present in A. scholaris. Interestingly, these isolates gave a strong activity with IC50 of 0.27 and 0.36 µg/mL, respectively. This could indicate that A. macrophylla might contain higher levels of villalstonine and macrocarpamine (Figure 3) than A. scholaris, although further research is needed for confirmation. The author suggested that these active alkaloids might act through a different mechanism to chloroquine and further investigation is needed to provide evidence [46]. The possible mechanism of bisindole alkaloids is the inhibition of hemozoin formation but in a manner different from chloroquine; hence, this explains the activity against chloroquine-resistant P. falciparum [47].
The in vivo activity of A. scholaris stem bark has also been studied. Abdullah et al. (2015) continued their previous in vitro study against the Plasmodium bergheii NK 65 strain in mice. The ethanolic extract of A. scholaris stem bark gave an ED50 of 121.94 mg/kg which was categorized as good activity [44]. According to Muñoz et al. (2000), in vivo antiplasmodial activity is classified as excellent if ED50 is ≤100 mg/kg BW/day, good if ED50 is ≤101–250 mg/kg BW/day, moderate if ED50 is 251–500 mg/kg BW/day, and inactive if ED50 is >500 mg/kg BW/day [48]. In addition, in an in vivo study, Intan et al. investigate the activity of a mixed extract of A. scholaris and Phyllanthus niruri (1:1). The extract was obtained by maceration with 70% ethanol, which reduced parasitemia and differential leukocyte count at a dose of 147.78 mg/kg [49]. Both studies have shown that the 70% ethanol extract of A. scholaris exerted a good in vivo antiplasmodial effect, although the second study used a mixture of two plant extracts. From the studies discussed, stem bark ethanolic extract should be the focus of further investigation against the P. falciparum chloroquine-resistant strain and the isolate, villalstonine, and macrocarpamine should be subjected to further in vivo study. The in vitro and in vivo studies of A. scholaris are summarized in Table 1.
The toxicity profile of A. scholaris has been studied for its methanolic and hydroalcoholic extract. Bello et al. (2016) conducted the acute and subacute toxicity studies of methanolic extract in Sprague–Dawley rats. In the acute study, the extract, at a dose of 2000 mg/kg BW, showed no toxicity, whereas in the subacute study, two female rats were recorded to have died at the highest dose of 1000 mg/kg BW after 28 days of oral administration. In histopathological studies, liver damage was found at the long-term administration of a high dose [50]. Baliga et al. (2004) investigated the acute and subacute toxicity of the hydroalcoholic extract of A. scholaris in mice and rats. In an acute study, the oral administration of 2000 mg/kg BW to Swiss albino mice showed no toxicity, whereas 1100 mg/Kg BW administered intraperitoneally resulted in animal deaths. The subacute toxicity test showed 30% mortality at a dose of 240 mg/kg BW given intraperitoneally, with damage in all organs [51]. From this study, oral administration of A. scholaris methanolic and hydroalcoholic extracts, as the administration route of the activity studies, showed low toxicity according to the OECD 425 guidelines [52].
Table
Table 1. Summary of Antiplasmodial Activity of A. scholaris, C. papaya, A. paniculata, and P. minima.
Table 1. Summary of Antiplasmodial Activity of A. scholaris, C. papaya, A. paniculata, and P. minima.
PlantPlant’s Part UsedSolventExtraction MethodAssayDose/ED50/IC50Active CompoundReference
Alstonia scholarisStem BarkEthanol 95%Maceration (triplicate)In vitro (P. falciparum chloroquine-sensitive 3D7 strain)IC50: 15.46 µg/mL (Moderate)-[43]
Stem BarkEthanol 70%Maceration (triplicate)In vitro (P. falciparum chloroquine-sensitive 3D7 strain)IC50: 0.165 µg/mL (Strong)-[44]
In vivo (P. berghei,
NK 65 strain in mice)		ED50: 121.94 mg/kg BW (Good)-
LeavesMethanolPercolationIn vitro (P. falciparum chloroquine-resistant K1)IC50: 210.8 µg/mL-[46]
Stem BarkIC50: 181.4 µg/mL-
Root BarkIC50: 370.2 µg/mL-
Isolates *--IC50: 0.27 µg/mL (1)
IC50: 0.36 µg/mL (2)		(1) Villalstonine
(2) Macrocarpamine
Carica papayaLeavesEthanol 70%Maceration (triplicate)In vitro (P. falciparum chloroquine-sensitive 3D7 strain)IC50: 0.177 µg/mL (Strong)-[44]
In vivo (P. berghei,
NK65 strain in mice)		ED50: 173.20 mg/kg BW (Good)-
LeavesEthanolPercolationIn vitro (P. falciparum)IC50: 46.23 µg/mL-[53]
StemIC50: 65.13 µg/mL-
LeavesMethanol 50%Not mentionedIn vivo (P. berghei,
NK65 strain in mice)		Dose: 100 mg/kg BW (>50% chemosuppresion)-[54]
LeavesSequential solvent: petroleum ether followed by dichlorometane, ethyl acetate, methanol, and waterMaceration (4-5 times, shaken continuously)In vitro (P. falciparum chloroquine-sensitive D10)IC50: 2.6 µg/mL (ethyl acetate)
IC50: 10.8 µg/mL (methanol)
IC50: 12.8 µg/mL (dichloromethane)
IC50: 16.4 µg/mL (petroleum ether)
IC50 > 50 µg/mL (water)		-[55]
Isolates--In vitro (P. falciparum chloroquine-sensitive D10)IC50: 3.58 µg/mL (1)
IC50: 6.88 µg/mL (2)		(1) Linolenic Acid
(2) Linoleic Acid
In vitro (P. falciparum chloroquine-resistant Dd2 strain)IC50: 4.40 µg/mL (1)
IC50: 6.80 µg/mL (2)
Isolate--In vitro (P. falciparum)IC50: 0.2 µMCarpaine[56]
In vivo (P. berghei ANKA strain)Dose: not specified, resulting only 11.9% reduction in parasitaemiaCarpaine
Isolate--In vitro (P. falciparum chloroquine-sensitive 3D7)IC50: 2.01 µg/mLCarpaine[57]
In vitro (P. falciparum chloroquine-resistant Dd2 strain)IC50: 2.19 µg/mL
Fruit rind/peelChloroformSoxhletIn vivo (P. berghei chloroquine-sensitive
ANKA strain)		Dose: 400 mg/kg BW (61.78% Chemosuppresion, moderate)-[58]
MethanolDose: 400 mg/kg BW (37.65% Chemosuppresion, Mild)-
Petroleum etherDose: 400 mg/kg BW (18.39% Chemosuppresion, Weak)-
RootChloroformSoxhletIn vivo (P. berghei chloroquine-sensitive
ANKA strain)		Dose: 400 mg/kg BW (43.77% Chemosuppresion, Mild)-
MethanolDose: 400 mg/kg BW (48.11% Chemosuppresion, Mild)-
WaterDose: 400 mg/kg BW (25.63% Chemosuppresion, Mild)-
LeavesWaterMacerationIn vivo (P. berghei,
NK65 strain in mice)		Dose: 350 mg/kg BW-[59]
LeavesEthanolSoxhletIn vitro (P. falciparum chloroquine-sensitive)IC50: 25–150 µg/mL-[60]
In vitro (P. falciparum chloroquine-resistant)IC50: 25–150 µg/mL-
Andrographis paniculataHerb
(aerial parts)		Purified ethyl acetate fraction from Ethanol 96% extractMaceration followed by liquid-liquid fractionation and further purificationIn vivo (P. berghei chloroquine-sensitive ANKA strain)Dose: 15 mg purified fraction per 300 mg tablet by wet granulation (78.16% inhibition) and 60 mg purified fraction per 150 mg tablet by solid dispersion method (80.35% inhibition)-[61]
Herb
(aerial parts)		Ethyl acetate fraction from ethanol 96% extractMaceration followed by liquid-liquid fractionationClinical trial Phase 1Equivalent to 35 mg andrographolide per 380 mg granule. 4 tablets twice daily for 4 days, classified as non-toxic & safe-[62]
Herb
(aerial parts)		Ethanol 50%PercolationIn vitro (P. falciparum of Papua strain (2300)Optimal dose at 200 µg/mL (10% parasitemia)-[63]
Not mentionedEthanol 50%PercolationClinical trial Phase 2Dose: 250 mg extract per 460 mg capsule → 94.2% (65 of 69) patients have negative parasitaemia on day 7-[64]
Herb
(aerial parts)		MethanolStirred at 4 °C overnightIn vitro (P. falciparum chloroquine-sensitive MRC-pf-20 and chloroquine-resistant MRC-pf-303)IC50: 7.2 µg/mL for both strain-[65]
In vivo (P. berghei ANKA strain)Dose: 7 mg/Kg BW, 39% parasitaemia at 12th day, control mice all died
Isolate--In vitro (P. falciparum chloroquine-resistant MRC-pf-303)IC50: 9.1 µMAndrographolide[66]
In vivo (P. bergheii ANKA strain)Dose: 15 mg/Kg BW, 46% parasitaemia at day 13–15, control mice all died
Isolate--In vitro (P. falciparum 3D7)IC50: 13.70 µMAndrographolide[67]
In vivo (P. berghei chloroquine-sensitive NK65)Dose: 5 mg/kg BW, 60.17% chemosuppresion
Whole plantn-HexaneSoxhletIn vitro (P. falciparum FCR-3 strain)--[68]
Chloroform100% inhibition at 0.05 mg/mL after 24 h
Methanol100% inhibition at 25 mg/mL after 48 h
Whole plantn-HexaneSoxhletIn vivo (P. berghei ANKA)--
Chloroform-
Methanol5 mg/Kg BW → delayed parasetaemia and all died at day 7 where control died at day 5
Physalis minimaIsolate *--In vitro (P. falciparum W2 clone)IC50: 2.8 µg/mLPhysalin B[69]
IC50: 55 µg/mLPhysalin D
IC50: 2.2 µg/mLPhysalin F
IC50: 6.7 µg/mLPhysalin G
In vivo (P. berghei strain NK65)Dose: 100 mg/kg → no decrease in parasitemiaPhysalin F
Dose: 100 mg/kg → 65% decrease in parasitemiaPhysalin D
* Isolate(s) were obtained from other plant species, but also present in the discussed plants.

4. Carica papaya L.

C. papaya of the Caricaceae family is a tree or shrub 8–10 m in height (Figure 4). It is native to tropical America but is cultivated all over the tropics and subtropics [70]. It is traditionally widely used as a treatment. In Indonesia, it is generally known as Pepaya. In Papua Island it is also locally known as peceren, eteradado, monofo, papaya, labseren, ogoseren, cacaveka, mbikin, senene ranau, and pepaya bllah [14].

4.1. Ethnopharmacology

C. papaya is used as a treatment for various conditions. Its leaf is used to treat dengue, inhibit cancer growth, treat malaria, for digestion problems and acne, increased appetite, to ease menstrual pain, relieve nausea, jaundice, kill viruses, and modulate immune response [14,74]. The fruit is used as a laxative and a treatment for indigestion [74]. The seed is used as a contraceptive for men and for abortion in women [75]. The flowers are utilized as digestive disorder treatments, diuretics, and tonics. In Papua Island, C. papaya leaf is used to combat malaria. In Waibon village, locals squeeze the yellowish leaves, add a pinch of salt, and consume the mixture orally. In other villages, young leaves are boiled with three glasses of water until reduced to one glass and then consumed orally [14,76].

4.2. Phytochemistry

Various parts of C. papaya are reported to contain caffeic acid, myricetin, quercetin, papain, α-tocopherol, benzyl isothiocyanate, kaempferol, squalene, phytol, campesterol, stigmasterol, β-sitosterol, hexadecanoid acid, γ-tocopherol, olean-12-ene, 13,17-cyclocursan-3-one, cycloartenol, and carpaine [77,78]. Another study characterized C. papaya seed oil and reported that it contains oleic, palmitic, stearic, linoleic, palmitoleic, arachidic, gadoleic, myristic, and margoric acid [79].

4.3. Antiplasmodial Activity

Antiplasmodial studies on different parts of C. papaya have been performed. Three studies used different extraction methods and examined the in vitro antiplasmodial activity of leaves. Abdillah et al. (2015), Ravikumar et al. (2012), and Kovendan et al. (2012) used maceration, percolation, and soxhlet extraction methods, respectively, with ethanol as solvent, and all were tested against P. falciparum. The IC50 of the ethanolic extract by maceration, percolation, and soxhlet methods were 0.18, 46.23, and 25 µg/mL, respectively [44,53,60]. Results varied, as the activity of the ethanolic extract obtained with the maceration method was classified as strong, while those with percolation and Soxhlet methods were classified as moderate [45]. A noticeable difference was due to the P. falciparum strain used. Abdillah et al. used the chloroquine-sensitive strain, Kovendan et al. used chloroquine-sensitive and resistant strains, whereas Ravikumar et al. did not mention the strain used. Another distinctive factor might be the concentration of ethanol used. Abdillah et al. used 70% ethanol, whereas the other studies did not mention the concentration. The difference in the concentration might well give a different chemical composition. The studies by Abdillah et al. and Kovendan et al. were compared since both performed phytochemical screening. Alkaloids, flavonoids, saponins, tannins, and triterpenoids were detected in both extracts. Abdillah et al. found coumarins, quinones, and steroids, but Kovendan et al. did not find these compounds. This might have resulted in the difference in activities, although more qualitative and quantitative compound analyses are needed.
Moreover, the stem was also subjected to in vitro testing by Ravikumar et al. using percolation extraction with ethanol extract; however, it demonstrated less activity with an IC50 of 65.13 µg/mL [53]. In addition, the in vitro activity in C. papaya leaves was investigated by Teng et al. (2019), who reported that the alkaloidal n-hexane extract was the most active against P. falciparum 3D7 and Dd2 strains with IC50 of 3.45 and 1.52 µg/mL, followed by dichloromethane extract with IC50 of 7.67 and 4.50 µg/mL, respectively. Carpaine (Figure 5A) was isolated from alkaloidal n-hexane extract and further screened against the P. falciparum 3D7 strain. It showed better activity with an IC50 of 2.01 µg/mL, suggesting the bioactive compound from the leaves [57]. Julianti et al. (2014) also isolated and tested carpaine in vitro against P. falciparum, which showed strong activity with an IC50 of 0.2 µM [56]. Melariri et al. (2011) tested several extracts obtained by sequential extraction and showed that the ethyl acetate extract was the most active with 2.6 µg/mL against P. falciparum chloroquine-sensitive D10 strain. Two isolates, linolenic acid and linoleic acid (Figure 5B,C) were then obtained and tested, which gave strong and good activity against P. falciparum chloroquine-resistant with IC50 of 3.58 and 6.88 µg/mL, respectively [55]. A previous study reported that fatty acids could enhance the neutrophil-mediated killing of the asexual blood forms of P. falciparum and that they might be a possible mechanism for linolenic and linonelic acid activity, although further confirmation is needed [80].
In vivo activities in three different plant organs were investigated by four research groups. In vivo assays for leaf extracts were investigated by Abdillah et al. (2015), Atanu et al. (2021), and Okpe et al. (2016). All studies used the maceration method, but with different solvents, namely 70% ethanol, 50% methanol, and water, respectively [44,54,59]. Abdillah et al. reported an ED50 of 173.2 mg/kg BW. According to the classification by Munoz et al., the activity of C. papaya ethanolic leaf extract was classified as good [48]. Atanu et al. and Okpe et al. suggest that the extracts gave suppressed parasitism by >50% at doses of 100 and 350 mg/kg BW, respectively [54,59]. Munoz et al. also stated that in vivo antiplasmodial activity can be classified as moderate, good, and very good if an extract suppressed parasitemia by >50% at doses of 500, 250, and 100 mg/kg per BW/day, respectively [48]. Based on that classification, the activities of methanolic and aqueous extract were considered very good and moderate, respectively. However, Okpe et al. only tested for one dose at a time, and the parasite suppression result was on par with the positive control (halofantrine 25 mg/kg BW); therefore, it is still possible to achieve parasite suppression ≥50% with a lower dose [59]. In addition, Julianti et al. (2014) investigated the carpaine isolate for its in vivo antiplasmodial activity; however, the results were somewhat disappointing as the treatment only reduced parasitemia by 11.9% despite the promising result of an in vitro study [56]. However, the exact dose was not mentioned; thus, we cannot conclude whether the low activity was due to the low dose given or other factors. From these studies, C. papaya leaf extract showed good potential as an antiplasmodial agent; however, the active compound must be further studied given the contrasting results of Carpaine in vitro and in vivo. In addition, the possibility of a synergistic effect of the compounds contained in the extract should also be considered. Other candidates as bioactive compounds should be considered and further examined because strong in vitro activity against chloroquine-resistant P. falciparum was found.
The fruit rind and roots of C. papaya were also studied for their in vivo antiplasmodial activities. In this study, Zeleke et al. (2017) obtained extracts through the Soxhlet method using three solvents, namely petroleum ether, chloroform, and methanol. The doses used were 400 mg/Kg BW. Petroleum ether, chloroform, and methanol extracts of fruit rind showed parasite suppression rates of 61.78%, 37.65%, and 18.39%, and extracts from roots had rates of 43.77%, 48.11%, and 25.63%, respectively. Only petroleum ether extract achieved a parasite suppression rate of >50%, which was classified as good [48,58]. Based on all these studies, the fruit rind and roots of C. papaya likely have less potential as antiplasmodial agents compared with leaves as summarized in Table 1. The antiplasmodial mechanism is still unclear; however, macrocylic dilactone alkaloids such as carpaine might work as a cation-chelating agent based on their structure [81]. From these studies, a direct comparison between methanolic, ethanolic, and ethyl acetate extracts might be performed against the P. falciparum chloroquine-resistant strain as the result from studies available varies. Moreover, the constituents of the most active extract should be determined to investigate the possibility of its synergistic action. Further in vivo studies must confirm the in vitro activity of the extracts and linolenic acid, which posed a strong activity in vitro against both P. falciparum chloroquine-sensitive and resistant strains.
The animal toxicity study of C. papaya leaf was summarized by Lim et al. (2021) in a systematic scoping review where, generally, leaf juice and aqueous extracts at doses up to 2000 mg/Kg are nontoxic in rats in acute and subacute studies [82,83,84]. The hydroalcoholic extract also showed very low toxicity with an LD50 of 5120 mg/kg BW when administered orally in chicks and no toxicity was noted in oral subchronic administration at a low dose [85]. The methanol sub-fraction from the chloroform extract of seeds showed no developmental toxicity or teratogenicity at the highest dose of 500 mg/kg BW [86]. The clinical evidence also suggests that oral consumption of C. papaya leaf, which is mostly aqueous extract or juice, is well tolerated [84].

5. Andrographis paniculata (Burm. f.)

A. paniculata of the Acanthaceae family is an herb that is up to 50 cm tall, annual, branched, and extremely bitter in all parts of the plant body (Figure 6) [87,88]. It is native to Taiwan, mainland China, India and Sri Lanka, is widely found in southern and southeast Asia, such as Bangladesh, China, Indonesia, Malaysia, Myanmar, Philippines, and Thailand [88,89,90,91]. It is commonly known as the king of bitter or kalmegh and, in Indonesia, it is known as sambiloto, sambiroto, and samiroto [14].

5.1. Ethnopharmacology

Commonly, aerial parts of A. paniculata are used to treat various infectious diseases such as leprosy, gonorrhea, respiratory tract infections, scabies, malaria, helminthiasis, herpes, peptic ulcers, and is used topically for skin infection and snake bites. It is also used as a treatment for irregular bowel habits, loss of appetite, alopecia, diabetes, jaundice, dyspepsia, and coughs [88,89,90,91,94]. In China, it was described as bitter and cold and considered antipyretic, detoxicant, anti-inflammatory, and detumescent. It is also thought to be used to remove “pathogenic heat” from the blood [90]. In Papua, A. paniculata is used to combat malaria. They use 10–15 leaves of sambiloto, boil them with water, and drink them two times a day until the disease is cured [24].

5.2. Phytochemistry

The main compound of A. paniculata is andrographolide, a diterpenoid lactone. Other known diterpenoid compounds are neoandrographolide, isoandrographolide, bis-andrographolides A-D, 14-deoxy-11-oxoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxyandrographolide, andrograpanin, andrographiside, andrographane, andrographic acid, andrographidines A-F, andrographidoids A-E, andropaniosides A & B, andrographatoside, andrographolactone, andopaniculosin A, andropaniculoside A, andropanolide, dehydroandrographolide, and paniculides A-C [95,96,97,98,99,100,101,102,103,104].
Some flavonoids are also found in A. paniculata, such as apigenin, cosmosiin, isoswertisin, luteolin, quercetin, skullcapflavone I, and onysilin [105]. Other constituents found in A. paniculata include α & β-sitosterol, β-daucosterol, caffeoylquinic acid, caffeic acid, cinnamic acid, ferulic acid, feruloylquinic acid, oleanolic acid, quinic acid, stigmasterol, and trans-cinnamic acid [96,106,107,108].

5.3. Antiplasmodial Activity

Among these four plants, A. paniculata is the most well studied for its antiplasmodial activity. In vitro studies were conducted by three research groups. Rahman et al. (1999) performed in vitro testing of the whole A. paniculata plant sequentially extracted by the Soxhlet method with n-hexane, chloroform, and methanol. Only chloroform and methanol extracts were tested and the results showed that the chloroform extract at a dose of 0.05 mg/mL had an inhibition rate of 100% after 24 h and at a dose of 0.025 mg/mL showed 100% inhibition after 48 h. The methanol extract at a dose of 0.4 mg/mL showed 100% inhibition after 24 h and at 0.025 mg/mL showed 100% inhibition after 72 h. However, the IC50 value was not determined [68]. Mishra et al. (2009) investigated the in vitro antiplasmodial activity of aerial parts of A. paniculata, extracted by the maceration method at 4 °C overnight with 98% methanol and tested against two strains of P. falciparum, the chloroquine-sensitive (MRC-pf-20) and choloroquine-resistant (MRC-pf-303). The IC50 was 7.2 µg/mL which, according to Ouattara et al., was considered strong or very active [45,65]. The results showed that the extract gave good activity for both strains, suggesting that the extract could well deal with the chloroquine-resistance mechanism of P. falciparum [65]. In another study, Zein et al. (2013) investigated the in vitro activity of A. paniculata extract through the maceration method for 3 h with 50% ethanol as a solvent against P. falciparum of Papua strain (2300). Accordingly, at a dose of 200 µg/mL, the parasite density was 10% compared with 38.7% in the control. However, this study also did not calculate the IC50 value [63].
The investigation of the in vivo activity was performed by Rahman et al. (1999), which further tested the methanolic extract for its in vivo antiplasmodial activity against P. berghei. At a dose of 5 mg/kg administered intraperitoneally for 4 days, the extract group showed delayed parasitemia where all mice died on day 7, compared with the control group without treatment where all mice died on day 5 [68]. This result is different to that reported by Mishra et al. (2009), who continued their investigation in vitro to evaluate the in vivo activity of the methanolic extract. Accordingly, at a dose of 7 mg/Kg BW, 39% parasitemia was observed on day 12, suggesting good suppression [65]. These two studies differed in the extraction method used. Sequential extraction by the Soxhlet method with n-hexane, chloroform, and methanol appeared to reduce the bioactive content in methanolic extract in the study by Rahman et al. (1999), compared with direct soaking overnight at 4 °C by Mishra et al. (2009), which appeared to be a better extraction method. In addition, the oral administration route appears to be superior to intraperitoneal administration [65,68]. Another in vivo study was performed by Widyawaruyanti et al. (2014), who used a purified ethyl acetate fraction from a 96% ethanol extract in tablet form. The study showed that 15 mg pure fraction per 300 mg tablet by wet granulation resulted in 78.16% parasite suppression and 60 mg pure fraction per 150 mg tablet by the solid dispersion method achieved 80.35% parasite suppression which, according to Munoz et al., was classified as very good [48,61]. The same research group further conducted a double-blind controlled crossover clinical trial (phase 1) for this pure fraction in 30 healthy volunteers, with a dose equivalent to 35 mg andrographolide per tablet. The study reported no difference in vital signs, hematological, and biochemical parameters when compared with the control group (placebo). In addition, increased appetite and better sleep were reported after the administration of the test tablet, which could be beneficial in uncomplicated malaria in which one of the symptoms is anorexia [62,109]. Hassan et al. (2019) studied the isolate, investigating the in vitro and in vivo activities of andrographolide (Figure 7). The IC50 of andrographolide against the P. falciparum 3D7 strain was 13.70 µM or roughly 4.8 µg/mL when converted, as the molar mass of andrographolide is 350.45 g/mol which was considered strong. The in vivo activity against P. berghei in infected mice with a dose of 5 mg/kg BW achieved 60.17% parasite suppression and, according to Munoz et al., it is considered very good [45,48,67]. This study is in line with the previous study by Mishra et al. (2011), in which the in vitro activity against the P. falciparum chloroquine-resistant strain was considered strong with an IC50 of 9.1 µM. The in vivo study against P. berghei at a dose of 15 mg/kg showed parasitemia level at 46% (>50% suppression) on day 13, where all controls died [66]. This shows that andrographolide could be the bioactive compound of A. paniculata demonstrating antiplasmodial activity as shown in Table 1, which has cytokine-modulating effects through the inhibition of GSK3β [67]. Nevertheless, other compounds may also contribute, or their interaction may eventually influence the extract activity. From these studies, the ethanolic extracts and ethyl acetate fraction might be investigated in a broader clinical study to confirm their efficacy for multi-compound product development, and andrographolide appears to be a definite bioactive compound, given its consistency in the in vitro and in vivo studies.
The acute toxicity study from the first true leaf ethanolic extract of A. paniculata in mice showed that a single oral administration with a dose of 5000 mg/Kg BW has no significant acute toxicological effect [110]. Another acute toxicity study showed that the methanolic extract of A. paniculata leaves at a dose of 5000 mg/Kg BW did not pose any treatment-related adverse clinical signs after 14 days of administration [111]. Moreover, the ethanolic extract of the aerial part of the plant did not show any testicular toxicity at a dose of 1000 mg/kg BW after 60 days of forced administration by buco-gastric formula [112]. In the acute toxicity study of its bioactive compound andrographolide, a dose of 500 mg/kg BW orally did not cause any toxicity; hence, it is considered relatively nontoxic [113]. Another study of doses up to 5 g/kg BW orally in mice did not show any signs of acute toxicity, whereas oral administration at a dose of up to 500 mg/Kg BW in Wistar rats for 21 days for subacute toxicity evaluation did not result in death or other signs of toxicity [114]. These studies suggest the relatively nontoxic properties of A. paniculata extracts and andrographolide as its bioactive compound.

6. Physalis minima L.

Physalis minima Linn. (Solanaceae) is a small herbaceous annual plant grown as a weed in crop fields, found widely in Indonesia, Malaysia, India, Afghanistan, tropical Africa, and Australia (Figure 8) [115,116,117,118]. The plant has a bitter taste and is known in Indonesia as ciplukan and, in Papua Island, it is locally known as pakpak, toki, daun nipon, cemploka, and seberi-nembai [14,117,118].

6.1. Ethnopharmacology

Traditionally, P. minima is used as an antiulcer, anti-inflammatory, antimalarial, antidiabetic, antimicrobial, diuretic, purgative, and cardioprotective plant [118,120]. The fruits and flowers are used to treat stomach pain and constipation. Herb paste is also applied to ear disorders [121,122]. In the Malay community, the decoction of the whole plant is used to cure cancer [123]. In Papua Island, Indonesia, P. minima is among the top four medicinal plants used to combat malaria; however, no specific usage was explained in the literature [14].

6.2. Phytochemistry

P. minima contains physalins A, B, D, F, H, I, L, and X, withaphysalins A, B, C, D, and E, and physalindicanols A and B [124,125,126,127]. Other studies reported that aerial parts of P. minima contain withaferin A, withanolide A, stigmasterol, sitosterol, withanone, dihydroxyphysalin B2-4, isophysalin B, withaminimin, 3-O-gylcoside of kaempferol and quercetin, and phygrin [126,128,129,130]. Another study reported the isolation of flavonoid compounds, namely, 5-methoxy-6,7-methylenedioxyflavone and 5,6,7-trimethoxyflavone [131].

6.3. Antiplasmodial Activity

To date, P. minima is less studied among the four plants used as antiplasmodial treatments in Papua Island; in fact, we have not found an antiplasmodial or antimalarial study of the plant. However, in Indonesia, P. minima is known as “ciplukan” and another species, Physalis angulate, is also called “ciplukan”. Lusakibanza et al. (2010) investigated the in vitro and in vivo antiplasmodial activities of P. angulata, whose methanolic and choloroform extracts demonstrated a strong in vitro activity according to Ouattara et al. against the chloroquine-sensitive P. falciparum strain 3D7 with IC50 of 1.25 and 1.96 µg/mL, and against the chloroquine-resistant P. falciparum strain W2 with IC50 of 3.02 and 2.00 µg/mL, respectively. The in vivo study showed that the aqueous extract at a dose of 300 mg/kg BW achieved 58.7% parasite suppression which, according to Munoz et al., is considered good [48,132]. Moreover, Sa et al. (2011) investigated the antiplasmodial properties of physalines B, D, F, and G. These compounds are also present in P. minima. The in vitro study showed that physaline F (Figure 9B) is the most active, with the lowest IC50 of 2.2 µg/mL, and physaline D (Figure 9A) is the less active among them with IC50 of 55 µg/mL. Interestingly, in the in vivo study, physaline D showed better activity with 65% parasite suppression at a dose of 100 mg/kg BW, which was considered very good according to Munoz et al., compared with physalin F with no parasite suppression at 100 mg/kg BW. Thus, suppression induced by physalin F might inhibit the antimalarial immune response to control infection in infected animals (Table 1); therefore, the better antimalarial activity of physalin D is probably due to its lack of immunosuppressive activity in mice [48,69]. Physalin D inhibits the P2X7 receptor [133]. Plasmodium infection releases large amounts of ATP, which results in sustained P2X7 receptor activation leading to a pro-inflammatory cycle [134]. Thus, treatment with P2 inhibitor that blocks these receptors will impair invasion [135]. This report is a good example of where the strong IC50 value of the in vitro analysis might not directly reflect a good in vivo activity as a more complex system was involved in the in vivo study, emphasizing the importance of the in vivo study. Given the lack of activity studies, a preliminary activity screening of the extracts is suggested.
In line with its pharmacological activity, toxicological data from P. minima is also limited. The water extract of P. minima leaves did not show any acute signs of toxicity at a dose of 2000 mg/kg BW after 14 days of oral administration [136]. The subchronic toxicity of the aqueous extract at a dose of 450 mg/Kg BW after 90 days of oral administration did not show any signs of hematologic toxicity, hepatotoxicity, or renal toxicity [137]. The lack of toxicity data for other organic solvent extracts such as methanol or ethanol, and its possible bioactive compound, physalins, is a challenge to the development of potential antiplasmodial agents from P. minima and to providing the safety profile.

7. Conclusions

Among these four medicinal plants traditionally used to treat malaria from Papua Island, Indonesia, A. paniculata is the most extensively studied and is a potential medicinal plant for antiplasmodial development, having completed the in vitro, in vivo, phases 1 and 2 of clinical trials, and a toxicity profile. The extract and its bioactive compound, andrographolide, have the potential to be developed as an antiplasmodial agent whether as a multicompound or single-compound product. A. scholaris and C. papaya also have the potential to be further investigated for determining their bioactive compounds as both posed good potential for antiplasmodial activities in vivo and have extensive toxicity data; however, the considered bioactive compounds must be evaluated for their in vivo antiplasmodial activity. P. minima is a less studied medicinal plant among the others; nevertheless, it allows for more potential investigation as this plant is also used extensively in traditional remedies to treat malaria.

Author Contributions

Data curation: R.B.I. and M.M.; Investigation: R.B.I., M.M. and M.I.B.; Supervision: M.M., M.I.B. and A.K.; Manuscript writing: R.B.I., M.M., M.I.B. and A.K.; Review: M.M., M.I.B. and A.K.; Editing: R.B.I. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. World Malaria Report 2021; World Health Organization: Geneva, Switzerland, 2021. [Google Scholar]
  2. World Health Organization. World Malaria Report 2020—20 Years of Global Progress & Challenges; World Health Organization: Geneva, Switzerland, 2020. [Google Scholar]
  3. World Health Organization. World Malaria Report 2019; World Health Organization: Geneva, Switzerland, 2019. [Google Scholar]
  4. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia Tahun 2020; Kementerian Kesehatan Republik Indonesia: Jakarta, Indonesia, 2021. [Google Scholar]
  5. Naß, J.; Efferth, T. Development of Artemisinin Resistance in Malaria Therapy. Pharmacol. Res. 2019, 146, 104275. [Google Scholar] [CrossRef]
  6. Wicht, K.J.; Mok, S.; Fidock, D.A. Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annu. Rev. Microbiol. 2020, 74, 431–454. [Google Scholar] [CrossRef]
  7. Buyon, L.E.; Elsworth, B.; Duraisingh, M.T. The Molecular Basis of Antimalarial Drug Resistance in Plasmodium vivax. Int. J. Parasitol. Drugs Drug Resist. 2021, 16, 23–37. [Google Scholar] [CrossRef]
  8. Elyazar, I.R.F.; Hay, S.I.; Baird, J.K. Malaria Distribution, Prevalence, Drug Resistance and Control in Indonesia Europe PMC Funders Group. Adv. Parasitol. 2011, 74, 41–175. [Google Scholar] [CrossRef]
  9. Fagbemi, K.A.; Adebusuyi, S.A.; Nderu, D.; Adedokun, S.A.; Pallerla, S.R.; Amoo, A.O.J.; Thomas, B.N.; Velavan, T.P.; Ojurongbe, O. Analysis of Sulphadoxine–Pyrimethamine Resistance-Associated Mutations in Plasmodium falciparum Isolates Obtained from Asymptomatic Pregnant Women in Ogun State, Southwest Nigeria. Infect. Genet. Evol. 2020, 85, 1–7. [Google Scholar] [CrossRef] [PubMed]
  10. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661. [Google Scholar] [CrossRef] [PubMed]
  11. Elfahmi; Woerdenbag, H.J.; Kayser, O. Jamu: Indonesian Traditional Herbal Medicine towards Rational Phytopharmacological Use. J. Herb. Med. 2014, 4, 51–73. [Google Scholar] [CrossRef]
  12. von Rintelen, K.; Arida, E.; Häuser, C. A Review of Biodiversity-Related Issues and Challenges in Megadiverse Indonesia and Other Southeast Asian Countries. Res. Ideas Outcomes 2017, 3, e20860. [Google Scholar] [CrossRef]
  13. Elyazar, I.R.F.; Gething, P.W.; Patil, A.P.; Rogayah, H.; Kusriastuti, R.; Wismarini, D.M.; Tarmizi, S.N.; Baird, K.J.; Hay, S.I. Plasmodium falciparum Malaria Endemicity in Indonesia in 2010. PLoS ONE 2011, 6, e0021315. [Google Scholar] [CrossRef]
  14. Budiarti, M.; Maruzy, A.; Mujahid, R.; Sari, A.N.; Jokopriyambodo, W.; Widayat, T.; Wahyono, S. The Use of Antimalarial Plants as Traditional Treatment in Papua Island, Indonesia. Heliyon 2020, 6, 1–10. [Google Scholar] [CrossRef]
  15. Khyade, M.S.; Kasote, D.M.; Vaikos, N.P. Alstonia Scholaris (L.) R. Br. and Alstonia macrophylla Wall. Ex G. Don: A Comparative Review on Traditional Uses, Phytochemistry and Pharmacology. J. Ethnopharmacol. 2014, 153, 1–18. [Google Scholar] [CrossRef]
  16. Zhao, Y.L.; Yang, Z.F.; Wu, B.F.; Shang, J.H.; Liu, Y.P.; Wang, X.H.; Luo, X.D. Indole Alkaloids from Leaves of Alstonia scholaris (L.) R. Br. Protect against Emphysema in Mice. J. Ethnopharmacol. 2020, 259, 112949. [Google Scholar] [CrossRef]
  17. iNaturalist. Alstonia scholaris (L.) R.Br. Observed in Singapore by Amodnargund. Available online: https://www.inaturalist.org/observations/107359940 (accessed on 16 January 2023).
  18. iNaturalist. Alstonia scholaris (L.) R.Br. Observed in Chinese Taipei by Hong. Available online: https://www.inaturalist.org/observations/114569913 (accessed on 16 January 2023).
  19. iNaturalist. Alstonia scholaris (L.) R.Br. Observed in Australia by Upollo. Available online: https://www.inaturalist.org/observations/124224199 (accessed on 16 January 2023).
  20. Pratap, B.; Chakraborthy, G.; Mogha, N. Complete Aspects of Alstonia scholaris. Int. J. Pharm. Tech. Res. 2013, 5, 17–26. [Google Scholar]
  21. Dey, A. Alstonia scholaris R.Br. (Apocynaceae): Phytochemistry and Pharmacology: A Concise Review Abhijit Dey. J. Appl. Pharm. Sci. 2011, 6, 51–57. [Google Scholar]
  22. Arulmozhi, S.; Mitra Mazumder, P.; Ashok, P.; Sathiya Narayanan, L. Pharmacological Activities of Alstonia scholaris Linn. (Apocynaceae)-A Review. Pharmacogn. Rev. 2007, 1, 163–170. [Google Scholar]
  23. Shang, J.H.; Cai, X.H.; Feng, T.; Zhao, Y.L.; Wang, J.K.; Zhang, L.Y.; Yan, M.; Luo, X.D. Pharmacological Evaluation of Alstonia scholaris: Anti-Inflammatory and Analgesic Effects. J. Ethnopharmacol. 2010, 129, 174–181. [Google Scholar] [CrossRef]
  24. Dinas Kesehatan Provinsi Papua. Tumbuhan Obat Tradisional Papua; Dinas Kesehatan Provinsi Papua: Jayapura, Indonesia, 2016; ISBN 978-602-60288-9-1. [Google Scholar]
  25. Shrinath Baliga, M. Alstonia scholaris Linn R Br in the Treatment and Prevention of Cancer: Past, Present, and Future. Integr. Cancer Ther. 2010, 9, 261–269. [Google Scholar] [CrossRef] [PubMed]
  26. Cai, X.H.; Du, Z.Z.; Luo, X.D. Unique Monoterpenoid Indole Alkaloids from Alstonia scholaris. Org. Lett. 2007, 9, 1817–1820. [Google Scholar] [CrossRef]
  27. Cai, X.H.; Liu, Y.-P.; Feng, T.; Luo, X.-D. Picrinine-Type Alkaloids from the Leaves of Alstonia scholaris. Chin. J. Nat. Med. 2008, 6, 20–22. [Google Scholar] [CrossRef]
  28. Cai, X.H.; Tan, Q.G.; Liu, Y.P.; Feng, T.; Du, Z.Z.; Li, W.Q.; Luo, X.D. A Cage-Monoterpene Indole Alkaloid from Alstonia scholaris. Org. Lett. 2008, 10, 577–580. [Google Scholar] [CrossRef]
  29. Cai, X.H.; Shang, J.H.; Feng, T.; Luoa, X.D. Novel Alkaloids from Alstonia scholaris. Z. Naturforsch. 2010, 65, 1164–1168. [Google Scholar] [CrossRef]
  30. Chen, Y.Y.; Yang, J.; Yang, X.W.; Khan, A.; Liu, L.; Wang, B.; Zhao, Y.L.; Liu, Y.P.; Ding, Z.T.; Luo, X.D. Alstorisine A, a nor-Monoterpenoid Indole Alkaloid from Cecidogenous Leaves of Alstonia scholaris. Tetrahedron Lett. 2016, 57, 1754–1757. [Google Scholar] [CrossRef]
  31. Feng, T.; Cai, X.H.; Zhao, P.J.; Du, Z.Z.; Li, W.Q.; Luo, X.D. Monoterpenoid Indole Alkaloids from the Bark of Alstonia scholaris. Planta Med. 2009, 75, 1537–1541. [Google Scholar] [CrossRef] [PubMed]
  32. Liu, L.; Chen, Y.Y.; Qin, X.J.; Wang, B.; Jin, Q.; Liu, Y.P.; Luo, X.D. Antibacterial Monoterpenoid Indole Alkaloids from Alstonia scholaris Cultivated in Temperate Zone. Fitoterapia 2015, 105, 160–164. [Google Scholar] [CrossRef] [PubMed]
  33. Pan, Z.; Qin, X.J.; Liu, Y.P.; Wu, T.; Luo, X.D.; Xia, C. Alstoscholarisines H-J, Indole Alkaloids from Alstonia scholaris: Structural Evaluation and Bioinspired Synthesis of Alstoscholarisine H. Org. Lett. 2016, 18, 654–657. [Google Scholar] [CrossRef]
  34. Qin, X.J.; Zhao, Y.L.; Lunga, P.K.; Yang, X.W.; Song, C.W.; Cheng, G.G.; Liu, L.; Chen, Y.Y.; Liu, Y.P.; Luo, X.D. Indole Alkaloids with Antibacterial Activity from Aqueous Fraction of Alstonia scholaris. Tetrahedron 2015, 71, 4372–4378. [Google Scholar] [CrossRef]
  35. Qin, X.J.; Zhao, Y.L.; Song, C.W.; Wang, B.; Chen, Y.Y.; Liu, L.; Li, Q.; Li, D.; Liu, Y.P.; Luo, X.D. Monoterpenoid Indole Alkaloids from Inadequately Dried Leaves of Alstonia scholaris. Nat. Prod. Bioprospect. 2015, 5, 185–193. [Google Scholar] [CrossRef]
  36. Yang, X.W.; Qin, X.J.; Zhao, Y.L.; Lunga, P.K.; Li, X.N.; Jiang, S.Z.; Cheng, G.G.; Liu, Y.P.; Luo, X.D. Alstolactines A–C, Novel Monoterpenoid Indole Alkaloids from Alstonia scholaris. Tetrahedron Lett. 2014, 55, 4593–4596. [Google Scholar] [CrossRef]
  37. Yang, X.W.; Yang, C.P.; Jiang, L.P.; Qin, X.J.; Liu, Y.P.; Shen, Q.S.; Chen, Y.B.; Luo, X.D. Indole Alkaloids with New Skeleton Activating Neural Stem Cells. Org. Lett. 2014, 16, 5808–5811. [Google Scholar] [CrossRef]
  38. Yang, X.W.; Luo, X.D.; Lunga, P.K.; Zhao, Y.L.; Qin, X.J.; Chen, Y.Y.; Liu, L.; Li, X.N.; Liu, Y.P. Scholarisines H–O, Novel Indole Alkaloid Derivatives from Long-Term Stored Alstonia scholaris. Tetrahedron 2015, 71, 3694–3698. [Google Scholar] [CrossRef]
  39. Yang, X.W.; Song, C.W.; Zhang, Y.; Khan, A.; Jiang, L.P.; Chen, Y.B.; Liu, Y.P.; Luo, X.D. Alstoscholarisines F and G, Two Unusual Monoterpenoid Indole Alkaloids from the Leaves of Alstonia scholaris. Tetrahedron Lett. 2015, 56, 6715–6718. [Google Scholar] [CrossRef]
  40. Zhu, G.Y.; Yao, X.J.; Liu, L.; Bai, L.P.; Jiang, Z.H. Alistonitrine A, a Caged Monoterpene Indole Alkaloid from Alstonia scholaris. Org. Lett. 2014, 16, 1080–1083. [Google Scholar] [CrossRef]
  41. Feng, T.; Cai, X.H.; Du, Z.Z.; Luo, X.D. Iridoids from the Bark of Alstonia scholaris. Helv. Chim. Acta 2008, 91, 2247–2251. [Google Scholar] [CrossRef]
  42. Xu, Y.; Feng, T.; Cai, X.-H.; Luo, X.-D. A New C13-Norisoprenoid from Leaves of Alstonia scholaris. Chin. J. Nat. Med. 2009, 7, 21–23. [Google Scholar] [CrossRef]
  43. Taek, M.M.; Tukan, G.D.; Prajogo, B.E.W.; Agil, M. Antiplasmodial Activity and Phytochemical Constituents of Selected Antimalarial Plants Used by Native People in West Timor Indonesia. Turk. J. Pharm. Sci. 2021, 18, 80–90. [Google Scholar] [CrossRef] [PubMed]
  44. Abdillah, S.; Tambunan, R.M.; Farida, Y.; Sandhiutami, N.M.D.; Dewi, R.M. Phytochemical Screening and Antimalarial Activity of Some Plants Traditionally Used in Indonesia. Asian Pac. J. Trop. Dis. 2015, 5, 454–457. [Google Scholar] [CrossRef]
  45. Ouattara, Y.; Sanon, S.; Traoré, Y.; Mahiou, V.; Azas, N.; Sawadogo, L. Antimalarial Activity of Swartzia Madagascariensis Desv. (Leguminosae), Combretum Glutinosum Guill. & Perr. (Combretaceae) and Tinospora Bakis Miers. (Menispermaceae), Burkina Faso Medicinal Plants. Afr. J. Tradit. Complement. Altern. Med. 2005, 3, 75–81. [Google Scholar] [CrossRef]
  46. Keawpradub, N.; Kirby, G.C.; Steele, J.C.P.; Houghton, P.J. Antiplasmodial Activity of Extracts and Alkaloids of Three Alstonia Species from Thailand. Planta Med. 1999, 65, 690–694. [Google Scholar] [CrossRef]
  47. Surur, A.S.; Huluka, S.A.; Mitku, M.L.; Asres, K. Indole: The After Next Scaffold of Antiplasmodial Agents? Drug Des. Dev. Ther. 2020, 14, 4855. [Google Scholar] [CrossRef]
  48. Muñoz, V.; Sauvain, M.; Bourdy, G.; Callapa, J.; Bergeron, S.; Rojas, I.; Bravo, J.A.; Balderrama, L.; Ortiz, B.; Gimenez, A.; et al. A Search for Natural Bioactive Compounds in Bolivia through a Multidisciplinary Approach. Part I. Evaluation of the Antimalarial Activity of Plants Used by the Chacobo Indians. J. Ethnopharmacol. 2000, 69, 127–137. [Google Scholar] [CrossRef]
  49. Intan, P.; Winarno, M.; Prihartini, N. Efek Ekstrak Campuran Kulit Batang Pulai (Alstonia scholaris) Dan Meniran (Phyllanthus niruri) Pada Mencit Swiss Webster Yang Diinfeksi Plasmodium berghei. J. Kefarmasian Indones. 2016, 6, 79–88. [Google Scholar] [CrossRef]
  50. Bello, I.; Bakkouri, A.; Tabana, Y.; Al-Hindi, B.; Al-Mansoub, M.; Mahmud, R.; Asmawi, M.Z. Acute and Sub-Acute Toxicity Evaluation of the Methanolic Extract of Alstonia scholaris Stem Bark. Med. Sci. 2016, 4, 4. [Google Scholar] [CrossRef] [PubMed]
  51. Baliga, M.S.; Jagetia, G.C.; Ulloor, J.N.; Baliga, M.P.; Venkatesh, P.; Reddy, R.; Rao, K.V.N.M.; Baliga, B.S.; Devi, S.; Raju, S.K.; et al. The Evaluation of the Acute Toxicity and Long Term Safety of Hydroalcoholic Extract of Sapthaparna (Alstonia scholaris) in Mice and Rats. Toxicol. Lett. 2004, 151, 317–326. [Google Scholar] [CrossRef]
  52. OECD. OECD Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure. In OECD Guidelines for the Testing of Chemicals; OECD Guidelines for the Testing of Chemicals, Section 4; OECD: Paris, France, 2022; ISBN 9789264071049. [Google Scholar]
  53. Ravikumar, S.; Inbaneson, S.J.; Suganthi, P. In Vitro Antiplasmodial Activity of Chosen Terrestrial Medicinal Plants against Plasmodium falciparum. Asian Pac. J. Trop. Biomed. 2012, 2, 252–256. [Google Scholar] [CrossRef]
  54. Atanu, F.O.; Idih, F.M.; Nwonuma, C.O.; Hetta, H.F.; Alamery, S.; El-Saber Batiha, G. Evaluation of Antimalarial Potential of Extracts from Alstonia boonei and Carica papaya in Plasmodium berghei-Infected Mice. Evid.-Based Complement. Altern. Med. 2021, 2021, 2599191. [Google Scholar] [CrossRef] [PubMed]
  55. Melariri, P.; Campbell, W.; Etusim, P.; Smith, P. Antiplasmodial Properties and Bioassay-Guided Fractionation of Ethyl Acetate Extracts from Carica papaya Leaves. J. Parasitol. Res. 2011, 2011, 104954. [Google Scholar] [CrossRef]
  56. Julianti, T.; De Mieri, M.; Zimmermann, S.; Ebrahimi, S.N.; Kaiser, M.; Neuburger, M.; Raith, M.; Brun, R.; Hamburger, M. HPLC-Based Activity Profiling for Antiplasmodial Compounds in the Traditional Indonesian Medicinal Plant Carica papaya L. J. Ethnopharmacol. 2014, 155, 426–434. [Google Scholar] [CrossRef]
  57. Teng, W.C.; Chan, W.; Suwanarusk, R.; Ong, A.; Ho, H.K.; Russell, B.; Rénia, L.; Koh, H.L. In Vitro Antimalarial Evaluations and Cytotoxicity Investigations of Carica papaya Leaves and Carpaine. Nat. Prod. Commun. 2019, 14, 33–36. [Google Scholar] [CrossRef]
  58. Zeleke, G.; Kebebe, D.; Mulisa, E.; Gashe, F. In Vivo Antimalarial Activity of the Solvent Fractions of Fruit Rind and Root of Carica papaya Linn (Caricaceae) against Plasmodium berghei in Mice. J. Parasitol. Res. 2017, 2017, 3121050. [Google Scholar] [CrossRef]
  59. Okpe, O.; Habila, N.; Ikwebe, J.; Upev, V.A.; Okoduwa, S.I.R.; Isaac, O.T. Antimalarial Potential of Carica papaya and Vernonia amygdalina in Mice Infected with Plasmodium berghei. J. Trop. Med. 2016, 2016, 8738972. [Google Scholar] [CrossRef]
  60. Kovendan, K.; Murugan, K.; Panneerselvam, C.; Aarthi, N.; Kumar, P.M.; Subramaniam, J.; Amerasan, D.; Kalimuthu, K.; Vincent, S. Antimalarial Activity of Carica papaya (Family: Caricaceae) Leaf Extract against Plasmodium falciparum. Asian Pac. J. Trop. Dis. 2012, 2, S306–S311. [Google Scholar] [CrossRef]
  61. Widyawaruyanti, A.; Asrory, M.; Ekasari, W.; Setiawan, D.; Radjaram, A.; Tumewu, L.; Hafid, A.F. In Vivo Antimalarial Activity of Andrographis paniculata Tablets. Procedia Chem. 2014, 13, 101–104. [Google Scholar] [CrossRef]
  62. Widyawaruyanti, A.; Jonosewojo, A.; Ilmi, H.; Tumewu, L.; Imandiri, A.; Widiastuti, E.; Dachliyati, L.; Budiman, M.F.; Setyawan, D.; Hafid, A.F.; et al. Safety Evaluation of an Antimalarial Herbal Product from Andrographis paniculata (AS201-01) in Healthy Volunteers. J. Basic Clin. Physiol. Pharmacol. 2021. [Google Scholar] [CrossRef]
  63. Zein, U.; Fitri, L.E.; Saragih, A. Comparative Study of Antimalarial Effect of Sambiloto (Andrographis paniculata) Extract, Chloroquine and Artemisinin and Their Combination against Plasmodium falciparum In-Vitro. Indones. J. Intern. Med. 2013, 45, 38–43. [Google Scholar]
  64. Makmur, T.; Siregar, F.A.; Siregar, S.; Lubis, I.A.; Bestari, R.; Zein, U. Open Clinical Trial of Sambiloto (Andrographis paniculata) Ethanolic Extract Capsules in Treatment of Malaria Patients in Batubara District, Indonesia. Med. Arch. 2022, 76, 419. [Google Scholar] [CrossRef]
  65. Mishra, K.; Dash, A.P.; Swain, B.K.; Dey, N. Anti-Malarial Activities of Andrographis paniculata and Hedyotis corymbosa Extracts and Their Combination with Curcumin. Malar. J. 2009, 8, 26. [Google Scholar] [CrossRef]
  66. Mishra, K.; Dash, A.P.; Dey, N. Andrographolide: A Novel Antimalarial Diterpene Lactone Compound from Andrographis paniculata and Its Interaction with Curcumin and Artesunate. J. Trop. Med. 2011, 2011, 579518. [Google Scholar] [CrossRef]
  67. Hassan, W.R.M.; Basir, R.; Ali; Embi, N. Sidek Anti-Malarial and Cytokine-Modulating Effects of Andrographolide in a Murine Model of Malarial Infection. Trop. Biomed. 2019, 36, 776–791. [Google Scholar]
  68. Rahman, N.N.N.A.; Furuta, T.; Kojima, S.; Takane, K.; Mohd, M.A. Antimalarial Activity of Extracts of Malaysian Medicinal Plants. J. Ethnopharmacol. 1999, 64, 249–254. [Google Scholar] [CrossRef]
  69. Sá, M.S.; De Menezes, M.N.; Krettli, A.U.; Ribeiro, I.M.; Tomassini, T.C.B.; Ribeiro Dos Santos, R.; De Azevedo, W.F.; Soares, M.B.P. Antimalarial Activity of Physalins B, D, F, and G. J. Nat. Prod. 2011, 74, 2269–2272. [Google Scholar] [CrossRef]
  70. World Flora Online. Carica papaya L. Available online: http://www.worldfloraonline.org/taxon/wfo-0000588009 (accessed on 6 December 2022).
  71. iNaturalist. Carica papaya L. Observed in Hong Kong by Viviang. Available online: https://www.inaturalist.org/observations/71054060 (accessed on 16 January 2023).
  72. iNaturalist. Carica papaya L. Observed in Cayman Islands by Caymanmatt. Available online: https://www.inaturalist.org/observations/108519374 (accessed on 16 January 2023).
  73. iNaturalist. Carica papaya L. Observed in United States of America by Ojos_y_manos. Available online: https://www.inaturalist.org/observations/83679263 (accessed on 16 January 2023).
  74. Aravind, G.; Bhowmik, D.; Duraviel, S.; Harish, G. Traditional and Medicinal Uses of Carica papaya. J. Med. Plants Stud. 2013, 1, 7–15. [Google Scholar]
  75. Ghaffarilaleh, V.; Fisher, D.; Henkel, R. Carica papaya Seed Extract Slows Human Sperm. J. Ethnopharmacol. 2019, 241, 111972. [Google Scholar] [CrossRef]
  76. Sarimole, E.; Martosupono, M.; Semangun, H.; Mangimbulude, J.C. Pengobatan Penyakit Malaria Dengan Menggunakan Beberapa Jenis Nabati Di Kabupaten Raja Ampat. In Raja Ampat and Future of Humanity (as a World Heritage), Proceedings of the Seminar Nasional Raja Ampat, Raja Ampat, Indonesia, 12–13 August 2014; Mangimbulude, J.C., Martosupono, M., Puspita, D., Nugroho, K.P.A.N., Eds.; Universitas Kristen Satya Wacana: Salatiga, Indonesia, 2014. [Google Scholar]
  77. Kong, Y.R.; Jong, Y.X.; Balakrishnan, M.; Bok, Z.K.; Weng, J.K.K.; Tay, K.C.; Goh, B.H.; Ong, Y.S.; Chan, K.G.; Lee, L.H.; et al. Beneficial Role of Carica papaya Extracts and Phytochemicals on Oxidative Stress and Related Diseases: A Mini Review. Biology 2021, 10, 287. [Google Scholar] [CrossRef]
  78. Khor, B.K.K.; Chear, N.J.Y.; Azizi, J.; Khaw, K.Y. Chemical Composition, Antioxidant and Cytoprotective Potentials of Carica papaya Leaf Extracts: A Comparison of Supercritical Fluid and Conventional Extraction Methods. Molecules 2021, 26, 1489. [Google Scholar] [CrossRef]
  79. Yanty, N.A.M.; Marikkar, J.M.N.; Nusantoro, B.P.; Long, K.; Ghazali, H.M. Physico-Chemical Characteristics of Papaya (Carica papaya L.) Seed Oil of the Hong Kong/Sekaki Variety. J. Oleo Sci. 2014, 63, 885–892. [Google Scholar] [CrossRef]
  80. Kumaratilake, L.M.; Ferrante, A.; Robinson, B.S.; Jaeger, T.; Poulos, A. Enhancement of Neutrophil-Mediated Killing of Plasmodium falciparum Asexual Blood Forms by Fatty Acids: Importance of Fatty Acid Structure. Infect. Immun. 1997, 65, 4152. [Google Scholar] [CrossRef]
  81. Uzor, P.F. Alkaloids from Plants with Antimalarial Activity: A Review of Recent Studies. Evid.-Based Complement. Altern. Med. 2020, 2020, 8749083. [Google Scholar] [CrossRef]
  82. Afzan, A.; Abdullah, N.R.; Halim, S.Z.; Rashid, B.A.; Semail, R.H.R.; Abdullah, N.; Jantan, I.; Muhammad, H.; Ismail, Z. Repeated Dose 28-Days Oral Toxicity Study of Carica papaya L. Leaf Extract in Sprague Dawley Rats. Molecules 2012, 17, 4326. [Google Scholar] [CrossRef]
  83. Ismail, Z.; Halim, S.Z.; Abdullah, N.R.; Afzan, A.; Abdul Rashid, B.A.; Jantan, I. Safety Evaluation of Oral Toxicity of Carica papaya Linn. Leaves: A Subchronic Toxicity Study in Sprague Dawley Rats. Evid.-Based Complement. Alternat. Med. 2014, 2014, 741470. [Google Scholar] [CrossRef]
  84. Lim, X.Y.; Chan, J.S.W.; Japri, N.; Lee, J.C.; Tan, T.Y.C. Carica Papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions. Evid.-Based Complement. Alternat. Med. 2021, 2021, 5511221. [Google Scholar] [CrossRef]
  85. Nghonjuyi, N.W.; Tiambo, C.K.; Taïwe, G.S.; Toukala, J.P.; Lisita, F.; Juliano, R.S.; Kimbi, H.K. Acute and Sub-Chronic Toxicity Studies of Three Plants Used in Cameroonian Ethnoveterinary Medicine: Aloe vera (L.) Burm. f. (Xanthorrhoeaceae) Leaves, Carica papaya L. (Caricaceae) Seeds or Leaves, and Mimosa pudica L. (Fabaceae) Leaves in Kabir Chicks. J. Ethnopharmacol. 2016, 178, 40–49. [Google Scholar] [CrossRef]
  86. Shrivastava, S.; Ansari, A.S.; Lohiya, N.K. Fertility, Developmental Toxicity and Teratogenicity in Albino Rats Treated with Methanol Sub-Fraction of Carica papaya Seeds. Indian J. Pharmacol. 2011, 43, 419–423. [Google Scholar] [CrossRef]
  87. World Flora Online. Andrographis paniculata (Burm.f.) Wall. Available online: http://www.worldfloraonline.org/taxon/wfo-0000534069 (accessed on 8 December 2022).
  88. Kumar, A.; Dora, J.; Singh, A.; Tripathi, R. A review on king of bitter (kalmegh). Int. J. Res. Pharm. Chem. 2012, 2, 116–124. [Google Scholar]
  89. Hossain, S.; Urbi, Z.; Karuniawati, H.; Mohiuddin, R.B.; Qrimida, A.M.; Allzrag, A.M.M.; Ming, L.C.; Pagano, E.; Capasso, R. Andrographis paniculata (Burm. f.) Wall. Ex Nees: An Updated Review of Phytochemistry, Antimicrobial Pharmacology, and Clinical Safety and Efficacy. Life 2021, 11, 348. [Google Scholar] [CrossRef]
  90. Akbar, S. Andrographis paniculata: A Review of Pharmacological Activities and Clinical Effects. Altern. Med. Rev. 2011, 16, 66–77. [Google Scholar]
  91. Hossain, M.S.; Urbi, Z.; Sule, A.; Rahman, K.M.H. Andrographis paniculata (Burm. f.) Wall. Ex Nees: A Review of Ethnobotany, Phytochemistry, and Pharmacology. Sci. World J. 2014, 2014, 274905. [Google Scholar] [CrossRef]
  92. iNaturalist. Andrographis paniculata (Burm.Fil.) Nees Observed in Thailand by Pakster. Available online: https://www.inaturalist.org/observations/114184625 (accessed on 18 January 2023).
  93. iNaturalist. Andrographis paniculata (Burm.Fil.) Nees Observed in India by Purab Chowdhury. Available online: https://www.inaturalist.org/observations/103810615 (accessed on 18 January 2023).
  94. Anju, D.; Jugnu, G.; Kavita, S.; Arun, N.; Sandeep, D. A Review on Medicinal Prospectives of Andrographis paniculata Nees. J. Pharm. Sci. Innov. 2012, 1, 1–4. [Google Scholar]
  95. Ji, L.L.; Wang, Z.; Dong, F.; Zhang, W.B.; Wang, Z.T. Andrograpanin, a Compound Isolated from Anti-Inflammatory Traditional Chinese Medicine Andrographis paniculata, Enhances Chemokine SDF-1alpha-Induced Leukocytes Chemotaxis. J. Cell. Biochem. 2005, 95, 970–978. [Google Scholar] [CrossRef] [PubMed]
  96. Intharuksa, A.; Arunotayanun, W.; Yooin, W.; Sirisa-ard, P. A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. Molecules 2022, 27, 4479. [Google Scholar] [CrossRef] [PubMed]
  97. Kuroyanagi, M.; Sato, M.; Ueno, A.; Nishi, K. Flavonoids from Andrographis paniculata. Chem. Pharm. Bull. 1987, 35, 4429–4435. [Google Scholar] [CrossRef]
  98. Xu, C.; Chou, G.X.; Wang, C.H.; Wang, Z.T. Rare Noriridoids from the Roots of Andrographis paniculata. Phytochemistry 2012, 77, 275–279. [Google Scholar] [CrossRef] [PubMed]
  99. My, N.T.T.; Hanh, T.T.H.; Cham, P.T.; Cuong, N.X.; Huong, T.T.; Quang, T.H.; Nam, N.H.; Minh, C. Van Andropaniosides A and B, Two New Ent-Labdane Diterpenoid Glucosides from Andrographis paniculata. Phytochem. Lett. 2020, 35, 37–40. [Google Scholar] [CrossRef]
  100. Shen, Y.H.; Li, R.T.; Xiao, W.L.; Gang-Xu; Lin, Z.W.; Zhao, Q.S.; Sun, H.D. Ent-Labdane Diterpenoids from Andrographis paniculata. J. Nat. Prod. 2006, 69, 319–322. [Google Scholar] [CrossRef]
  101. Wang, G.C.; Wang, Y.; Williams, I.D.; Sung, H.H.Y.; Zhang, X.Q.; Zhang, D.M.; Jiang, R.W.; Yao, X.S.; Ye, W.C. Andrographolactone, a Unique Diterpene from Andrographis paniculata. Tetrahedron Lett. 2009, 50, 4824–4826. [Google Scholar] [CrossRef]
  102. Pramanick, S.; Banerjee, S.; Achari, B.; Das, B.; Sen, A.K.; Mukhopadhyay, S.; Neuman, A.; Prangé, T. Andropanolide and Isoandrographolide, Minor Diterpenoids from Andrographis paniculata: Structure and X-Ray Crystallographic Analysis. J. Nat. Prod. 2006, 69, 403–405. [Google Scholar] [CrossRef] [PubMed]
  103. Nishi, K.; Kuroyanagi, M.; Sugiyama, S.; Umehara, K.; Ueno, A. Cell Differentiation-Inducing Diterpenes from Andrographis paniculata Nees. Chem. Pharm. Bull. 1994, 42, 1216–1225. [Google Scholar] [CrossRef]
  104. Allison, A.J.; Butcher, D.N.; Connolly, J.D.; Overton, K.H. Paniculides A, B, and C, Bisabolenoid Lactones from Tissue Cultures of Andrographis paniculata. Chem. Commun. 1968, 23, 1493. [Google Scholar] [CrossRef]
  105. Wu, T.S.; Chern, H.J.; Damu, A.G.; Kuo, P.C.; Su, C.R.; Lee, E.J.; Teng, C.M. Flavonoids and Ent-Labdane Diterpenoids from Andrographis paniculata and Their Antiplatelet Aggregatory and Vasorelaxing Effects. J. Asian Nat. Prod. Res. 2008, 10, 17–24. [Google Scholar] [CrossRef]
  106. Xu, C.; WAng, Z.-T. Chemical Constituents from Roots of Andrographis paniculata. Yao Xue Xue Bao 2011, 46, 317–321. [Google Scholar]
  107. Chua, L.S.; Yap, K.C.; Jaganath, I.B. Comparison of Total Phenolic Content, Scavenging Activity and HPLC-ESI-MS/MS Profiles of Both Young and Mature Leaves and Stems of Andrographis paniculata. Nat. Prod. Commun. 2013, 8, 1725–1729. [Google Scholar] [CrossRef]
  108. Koteswara Rao, Y.; Vimalamma, G.; Venkata Rao, C.; Tzeng, Y.M. Flavonoids and Andrographolides from Andrographis paniculata. Phytochemistry 2004, 65, 2317–2321. [Google Scholar] [CrossRef] [PubMed]
  109. Ogutu, B.; Juma, E.; Obonyo, C.; Jullien, V.; Carn, G.; Vaillant, M.; Taylor, W.R.J.; Kiechel, J.R. Fixed Dose Artesunate Amodiaquine—A Phase IIb, Randomized Comparative Trial with Non-Fixed Artesunate Amodiaquine. Malar. J. 2014, 13, 1–13. [Google Scholar] [CrossRef] [PubMed]
  110. Worasuttayangkurn, L.; Nakareangrit, W.; Kwangjai, J.; Sritangos, P.; Pholphana, N.; Watcharasit, P.; Rangkadilok, N.; Thiantanawat, A.; Satayavivad, J. Acute Oral Toxicity Evaluation of Andrographis paniculata-Standardized First True Leaf Ethanolic Extract. Toxicol. Rep. 2019, 6, 426. [Google Scholar] [CrossRef] [PubMed]
  111. Chandrasekaran, C.V.; Thiyagarajan, P.; Sundarajan, K.; Goudar, K.S.; Deepak, M.; Murali, B.; Joshua Allan, J.; Agarwal, A. Evaluation of the Genotoxic Potential and Acute Oral Toxicity of Standardized Extract of Andrographis paniculata (KalmColdTM). Food Chem. Toxicol. 2009, 47, 1892–1902. [Google Scholar] [CrossRef]
  112. Burgos, R.A.; Caballero, E.E.; Sánchez, N.S.; Schroeder, R.A.; Wikman, G.K.; Hancke, J.L. Testicular Toxicity Assesment of Andrographis paniculata Dried Extract in Rats. J. Ethnopharmacol. 1997, 58, 219–224. [Google Scholar] [CrossRef]
  113. Al Batran, R.; Al-Bayaty, F.; Al-Obaidi, M.M.J.; Abdulla, M.A. Acute Toxicity and the Effect of Andrographolide on Porphyromonas Gingivalis-Induced Hyperlipidemia in Rats. Biomed. Res. Int. 2013, 2013, 594012. [Google Scholar] [CrossRef]
  114. Bothiraja, C.; Pawar, A.P.; Shende, V.S.; Joshi, P.P. Acute and Subacute Toxicity Study of Andrographolide Bioactive in Rodents: Evidence for the Medicinal Use as an Alternative Medicine. Comp. Clin. Pathol. 2013, 22, 1123–1128. [Google Scholar] [CrossRef]
  115. World Flora Online. Physalis minima L. Available online: http://www.worldfloraonline.org/taxon/wfo-0001024837 (accessed on 8 December 2022).
  116. Patel, T.; Shah, K.; Jiwan, K.; Shrivastava, N. Study on the Antibacterial Potential of Physalis minima Linn. Indian J. Pharm. Sci. 2011, 73, 111. [Google Scholar] [CrossRef]
  117. Alegantina, S.; Setyorini, H.A.; Oktoberia, I.S.; Winarsih; Aini, N. Physalis minima L. Profile from Various Ethnics in 9 (Nine) Provinces Indonesia by HPLCand Chemometric. Media Penelit. Dan Pengemb. Kesehat. 2021, 31, 17–26. [Google Scholar]
  118. Khan, M.A.; Khan, H.; Khan, S.; Mahmood, T.; Khan, P.M.; Jabar, A. Anti-Inflammatory, Analgesic and Antipyretic Activities of Physalis minima Linn. J. Enzym. Inhib. Med. Chem. 2009, 24, 632–637. [Google Scholar] [CrossRef]
  119. Habib, A. Wildgooseberry (Physalis minima). Available online: https://www.inaturalist.org/observations/23892499#data_quality_assessment (accessed on 9 December 2022).
  120. Shil, D.; Sarma, T.; Roy, S.D.; Chakraborty, J.; Das, S.R.C.; Das, T.; Rohman, T.A. Exploring Quality Control Standards and Potential Antibacterial Property of Different Extracts of the Root of Physalis minima L. Int. J. Res. Pharm. Sci. 2021, 12, 2350–2360. [Google Scholar] [CrossRef]
  121. Chothani, D.L.; Vaghasiya, H.U. A Phyto-Pharmacological Overview on Physalis minima Linn. Indian J. Nat. Prod. Resour. 2012, 3, 477–482. [Google Scholar]
  122. Parkash, V.; Aggarwal, A. Traditional Uses of Ethnomedicinal Plants of Lower Foot-Hills of Himachal Pradesh-I. Indian J. Tradit. Knowl. 2010, 9, 519–521. [Google Scholar]
  123. Zakaria, M.; Mohd, M.A. Traditional Malay Medicinal Plants; Institut Terjemahan & Buku Malaysia: Kuala Lumpur, Malaysia, 2015; ISBN 978-9-83-068385-0. [Google Scholar]
  124. Sinha, S.C.; Ray, A.B. Chemical Constituents of Physalis minima Var. Indica. J. Indian Chem. Soc. 1988, LXV, 740–741. [Google Scholar] [CrossRef]
  125. Ooi, K.L.; Tengku Muhammad, T.S.; Sulaiman, S.F. Physalin F from Physalis minima L. Triggers Apoptosis-Based Cytotoxic Mechanism in T-47D Cells through the Activation Caspase-3- and c-Myc-Dependent Pathways. J. Ethnopharmacol. 2013, 150, 382–388. [Google Scholar] [CrossRef]
  126. Choudhary, M.I.; Yousaf, S.; Ahmed, S.; Samreen; Yasmeen, K. Atta-ur-Rahmang Antileishmanial Physalins from Physalis minima. Chem. Biodivers. 2005, 2, 1164–1173. [Google Scholar] [CrossRef]
  127. Sen, G.; Pathak, H.D. Physalin L, a 13,14-Seco-16,24 Cyclosteroid from Physalis minima. Phytochemistry 1995, 39, 1245–1246. [Google Scholar] [CrossRef]
  128. Misra, L.N.; Lal, P.; Kumar, D. Isolation and Characterization of Steroids of Nutraceutical Value in Physalis minima. J. Food Sci. Nutr. 2006, 11, 133–139. [Google Scholar] [CrossRef]
  129. Gottlieb, H.E.; Cojocaru, M.; Sinha, S.C.; Saha, M.; Bagchi, A.; Ali, A.; Ray, A.B. Withaminimin, a Withanolide from Physalis minima. Phytochemistry 1987, 26, 1801–1804. [Google Scholar] [CrossRef]
  130. Basey, K.; McGaw, B.A.; Woolley, J.G. Phygrine, an Alkaloid from Physalis Species. Phytochemistry 1992, 31, 4173–4176. [Google Scholar] [CrossRef]
  131. Ser, N.A. Flavonoids from Physalis minima. Phytochemistry 1988, 27, 3708–3709. [Google Scholar] [CrossRef]
  132. Lusakibanza, M.; Mesia, G.; Tona, G.; Karemere, S.; Lukuka, A.; Tits, M.; Angenot, L.; Frédérich, M. In Vitro and In Vivo Antimalarial and Cytotoxic Activity of Five Plants Used in Congolese Traditional Medicine. J. Ethnopharmacol. 2010, 129, 398–402. [Google Scholar] [CrossRef] [PubMed]
  133. Arruda, J.C.C.; Rocha, N.C.; Santos, E.G.; Ferreira, L.G.B.; Bello, M.L.; Penido, C.; Costa, T.E.M.M.; Santos, J.A.A.; Ribeiro, I.M.; Tomassini, T.C.B.; et al. Physalin Pool from Physalis angulata L. Leaves and Physalin D Inhibit P2X7 Receptor Function in Vitro and Acute Lung Injury in Vivo. Biomed. Pharmacother. 2021, 142, 112006. [Google Scholar] [CrossRef] [PubMed]
  134. Savio, L.E.B.; de Andrade Mello, P.; da Silva, C.G.; Coutinho-Silva, R. The P2X7 Receptor in Inflammatory Diseases: Angel or Demon? Front. Pharmacol. 2018, 9, 52. [Google Scholar] [CrossRef]
  135. Levano-Garcia, J.; Dluzewski, A.R.; Markus, R.P.; Garcia, C.R.S. Purinergic Signalling Is Involved in the Malaria Parasite Plasmodium falciparum Invasion to Red Blood Cells. Purinergic Signal. 2010, 6, 365–372. [Google Scholar] [CrossRef]
  136. Zafirah Ismail, N.; Arsad, H.; Afiqah Lokman, N.; Izzati Jaafar, N.; Hasyimah Haron, N. Preliminary Acute Oral Toxicity Study of The Water Extract of Physalis minima Leaves. J. Biol. Sci. Opin. 2018, 6, 111–115. [Google Scholar] [CrossRef]
  137. Soeharto, S.; Nugrahenny, D.; Permatasari, N.; Mayangsari, E. Subchronic Toxicity of the Physalis minima Leaves. Res. J. Life Sci. 2018, 5, 77–82. [Google Scholar] [CrossRef]
Plants 12 01813 g001 550
Figure 1. Flow diagram of the study.
Figure 1. Flow diagram of the study.
Plants 12 01813 g001
Plants 12 01813 g002 550
Figure 2. Alstonia scholaris (L.) R.Br. [17,18,19].
Figure 2. Alstonia scholaris (L.) R.Br. [17,18,19].
Plants 12 01813 g002
Plants 12 01813 g003 550
Figure 3. Structures of villalstonine (A) and macrocarpamine (B).
Figure 3. Structures of villalstonine (A) and macrocarpamine (B).
Plants 12 01813 g003
Plants 12 01813 g004 550
Figure 4. Carica papaya L. [71,72,73].
Figure 4. Carica papaya L. [71,72,73].
Plants 12 01813 g004
Plants 12 01813 g005 550
Figure 5. Structures of carpaine (A), linolenic acid (B), and linoleic acid (C).
Figure 5. Structures of carpaine (A), linolenic acid (B), and linoleic acid (C).
Plants 12 01813 g005
Plants 12 01813 g006 550
Figure 6. Andrographis paniculata (Burm. f) [92,93].
Figure 6. Andrographis paniculata (Burm. f) [92,93].
Plants 12 01813 g006
Plants 12 01813 g007 550
Figure 7. Structure of andrographolide.
Figure 7. Structure of andrographolide.
Plants 12 01813 g007
Plants 12 01813 g008 550
Figure 8. Physalis minima L. [119].
Figure 8. Physalis minima L. [119].
Plants 12 01813 g008
Plants 12 01813 g009 550
Figure 9. Structures of physalin D (A) and physalin F (B).
Figure 9. Structures of physalin D (A) and physalin F (B).
Plants 12 01813 g009
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Indradi, R.B.; Muhaimin, M.; Barliana, M.I.; Khatib, A. Potential Plant-Based New Antiplasmodial Agent Used in Papua Island, Indonesia. Plants 2023, 12, 1813. https://doi.org/10.3390/plants12091813

AMA Style

Indradi RB, Muhaimin M, Barliana MI, Khatib A. Potential Plant-Based New Antiplasmodial Agent Used in Papua Island, Indonesia. Plants. 2023; 12(9):1813. https://doi.org/10.3390/plants12091813

Chicago/Turabian Style

Indradi, Raden Bayu, Muhaimin Muhaimin, Melisa Intan Barliana, and Alfi Khatib. 2023. "Potential Plant-Based New Antiplasmodial Agent Used in Papua Island, Indonesia" Plants 12, no. 9: 1813. https://doi.org/10.3390/plants12091813

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop